Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL28641046 | 0.96 | CYP1A2 (0.31) | CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5779580 | 0.74 | — | — | |
| SCHEMBL8195363 | 0.73 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL8521345 | 0.72 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL2070772 | 0.71 | — | — | |
| SCHEMBL15337522 | 0.70 | — | — | |
| SCHEMBL10438993 | 0.70 | SMN1; SMN2 (0.38) | CYP1A2SMN1; SMN2 | |
| SCHEMBL6200548 | 0.70 | — | — | |
| SCHEMBL321303 | 0.70 | LMNA (0.32) | — | |
| SCHEMBL13659733 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116200183-B | High-efficiency variable-viscosity fracturing fluid for deep coal bed gas development and integrated construction method | 四川申和新材料科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-114890945-B | Method for synthesizing nadifloxacin intermediate | 大连万福制药有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116200183-A | High-efficiency variable-viscosity fracturing fluid for deep coal bed gas development and integrated construction method | 四川申和新材料科技有限公司 | 2023-06-02 | — | — | CN | claimed |
| EP-1513833-B1 | NOVEL 3-(4-OXO-4H-CHROMEN-2-YL)-(1H)-QUINOLINE-4-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2006-04-19 | — | — | EP | claimed |
| EP-1513833-A1 | NOVEL 3-(4-OXO-4H-CHROMEN-2-YL)-(1H)-QUINOLINE-4-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier (FR) | 2005-03-16 | — | — | EP | claimed |
| WO-2004000834-A1 | NOVEL 3-(4-OXO-4H-CHROMEN-2-YL)-(1H)-QUINOLINE-4-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2003-12-31 | — | — | WO | claimed |
| EP-0267432-B1 | ANTIBACTERIALLY ACTIVE PYRIDO-BENZOTHIAZINE DERIVATIVES WITH LONG TERM ACTION | MEDIOLANUM FARMACEUTICI s.r.l. (IT) | 1991-12-27 | — | — | EP | claimed |
| EP-0086723-B1 | SUBSTITUTED PYRIMIDONES AND THEIR SALTS, THEIR PREPARATION, THEIR APPLICATION AS MEDICAMENTS, COMPOSITIONS CONTAINING THEM AND INTERMEDIATES OBTAINED | ROUSSEL-UCLAF (FR) | 1987-04-22 | — | — | EP | claimed |
| EP-0086723-A2 | Substituted pyrimidones and their salts, their preparation, their application as medicaments, compositions containing them and intermediates obtained | ROUSSEL-UCLAF (FR) | 1983-08-24 | — | — | EP | claimed |
| CN-115433124-B | Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline | 常州佳德医药科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-116200183-B | High-efficiency variable-viscosity fracturing fluid for deep coal bed gas development and integrated construction method | 四川申和新材料科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| US-11925690-B2 | Bifunctional molecules for targeting Rpn11 | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-12 | — | — | US | disclosed |
| WO-2024022487-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-0090656-A1 | Penicillins, a process for the preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1983-10-05 | — | — | EP | disclosed |
| US-4404205-A | CARDIOTONIC AGENTS; ANGINA PECTORIS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1983-09-13 | — | — | US | disclosed |
| EP-0086723-A2 | Substituted pyrimidones and their salts, their preparation, their application as medicaments, compositions containing them and intermediates obtained | ROUSSEL-UCLAF (FR) | 1983-08-24 | — | — | EP | disclosed |
| US-4367229-A | 3-Substituted-tetrahydro-pyrrolo[1,2-a]pyrimidines and pharmaceutical compositions | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1983-01-04 | — | — | US | disclosed |
| US-4046577-A | PHOTOREACTIVE COMPOSITIONS COMPRISING POLYMERS CONTAINING ALKOXYAROMATIC GLYOXY GROUPS | THE RICHARDSON COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
| US-3984548-A | Substituted pyrido[1,2,3,-de]-1,4-benzoxazines as bactericides | RIKER LABORATORIES, INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | CYP1A2 3773/4885ALDH1A1 1427/4885SMN1; SMN2 1168/4885 |
| US-11925690-B2 | Bifunctional molecules for targeting Rpn11 | RPN1, RPP30, UBQLN1 | CYP1A2 4675/4885ALDH1A1 2199/4885SMN1; SMN2 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.